Targets › PTGER4
4 programs from 4 companies in 4 trials: 2 Phase 2, 1 Phase 4, 1 Phase 1; Other, Oncology; next expected readout Dec 2026.
Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. (UniProt, P35408)
Open in Phaseline: the race on PTGER4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| HaEmek Medical Center, Israel | Dinoprostone Prostaglandin E2 receptor agonist | PTGER1, PTGER4, PTGER2, PTGER3 | Phase 4 | Induction of Labor | Jan 2027 |
| Ghufran Dhari Awad | Prostaglandin E1 Prostaglandin E1 receptor agonist | PTGER1, PTGER2, PTGER3, PTGER4 | Phase 2 | Accelerated Orthodontic Tooth Movement | Dec 2026 |
| National Cancer Institute (NCI) | TPST-1495 Dual EP2/EP4 antagonist; prostaglandin E2 receptor antagonist | PTGER2, PTGER4 | Phase 2 | Colorectal Carcinoma | Jun 2027 |
| Rottapharm Biotech | Vorbipiprant (CR6086) Prostanoid EP4 receptor antagonist | PTGER4 | Phase 1 | Refractory Metastatic Colorectal Cancer | Dec 2026 |
Accelerated Orthodontic Tooth Movement (1) Induction of Labor (1) Colorectal Carcinoma (1) Refractory Metastatic Colorectal Cancer (1)
small molecule (3), mixed (1)
Ghufran Dhari Awad (1) HaEmek Medical Center, Israel (1) National Cancer Institute (NCI) (1) Rottapharm Biotech (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.